Suppr超能文献

普萘洛尔与胺碘酮在抑制心肌梗死后室性心律失常疗效的比较。

Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction.

作者信息

Fournier C, Brunet M, Bah M, Kindermans M, Boujon B, Tournadre P, Giudicelli J F, Blondeau M

机构信息

Department of Cardiology, Hôpital de Bicêtre, Paris, France.

出版信息

Eur Heart J. 1989 Dec;10(12):1090-100. doi: 10.1093/oxfordjournals.eurheartj.a059431.

Abstract

The purpose of this prospective randomized trial was to compare the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias during the first 6 months following myocardial infarction (MI). 97 patients were treated with either amiodarone (n = 48) or propranolol (n = 49) starting on the 9th day following MI. Holter monitoring was carried out on four occasions: on D7, D21, D90 and D180. There was no statistical difference in the incidence of 'major' arrhythmias (an average of at least 10 ventricular premature complexes (VPCs) h-1, multiform or paired VPCs or runs) between the two groups on D7. A significant difference in favour of amiodarone became apparent at D180 (P = 0.04). Patients were also classified according to whether treatment failed or was successful. 'Success' was recorded when arrhythmias remained minor or became minor (less than 10 uniform VPCs h-1) and 'failure' when arrhythmias remained major or became major, or when patients were withdrawn because of side-effects, or lost to follow-up. The difference remained in favour of amiodarone (P = 0.03 at D21; P = 0.05 at D90; P = 0.06 at D180). Evaluation of the percentage reduction in the number of VPCs at D21, D90 or D180 compared with D7 showed superiority of amiodarone at D90 (P less than 0.01) and D180 (P less than 0.04). In this study, the overall effect of amiodarone on ventricular arrhythmias following MI was shown to be superior to that of propranolol.

摘要

这项前瞻性随机试验的目的是比较普萘洛尔和胺碘酮在心肌梗死(MI)后前6个月抑制室性心律失常的疗效。97例患者在心肌梗死后第9天开始接受胺碘酮治疗(n = 48)或普萘洛尔治疗(n = 49)。进行了4次动态心电图监测:在第7天、第21天、第90天和第180天。在第7天,两组之间“严重”心律失常(平均至少10次室性早搏(VPCs)/小时、多形性或成对的室性早搏或连发)的发生率无统计学差异。在第180天,胺碘酮组明显更具优势(P = 0.04)。患者还根据治疗失败或成功进行分类。当心律失常保持轻微或变为轻微(每小时少于10次单形性室性早搏)时记录为“成功”,当心律失常保持严重或变为严重,或患者因副作用退出或失访时记录为“失败”。这种差异仍然有利于胺碘酮(第21天P = 0.03;第90天P = 0.05;第180天P = 0.06)。与第7天相比,评估第21天、第90天或第180天时室性早搏数量减少的百分比,结果显示胺碘酮在第90天(P < 0.01)和第180天(P < 0.04)具有优势。在这项研究中,胺碘酮对心肌梗死后室性心律失常的总体疗效优于普萘洛尔。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验